Literature DB >> 15946336

Periventricular white matter flumazenil binding and postoperative outcome in hippocampal sclerosis.

Alexander Hammers1, Matthias J Koepp, David J Brooks, John S Duncan.   

Abstract

PURPOSE: In patients with hippocampal sclerosis (HS), anterior temporal lobe resection offers the possibility of a long-lasting suppression of seizures in two thirds of patients. White matter (WM) [11C]flumazenil volume of distribution (FMZ-Vd) reflects the number of neuronal cell bodies in WM. Our objective was to correlate WM FMZ-Vd in patients with unilateral HS and postsurgical outcome.
METHODS: We performed [11C]FMZ-PET in 15 patients with refractory mesial temporal lobe epilepsy (mTLE) and a quantitative MRI diagnosis of unilateral HS subsequently histologically verified in all cases. Median follow-up was 7 years (range, 6-9 years). Metabolite-corrected arterial plasma input functions and spectral analysis were used to generate parametric images of [11C]FMZ-Vd. Statistical parametric mapping (SPM99) with explicit masking was used to investigate the entire brain volume including WM.
RESULTS: Eight patients had Engel class IA outcome (completely seizure free since surgery), and seven were not seizure free. Comparison of seizure-free patients with those who continued to have seizures after surgery revealed areas of increased FMZ binding around the posterior horns of the ipsilateral (z=3.7) and contralateral (z=2.7) ventricles in those with suboptimal outcomes.
CONCLUSIONS: Preoperative [11C]FMZ-PET can detect periventricular increases of WM FMZ binding, implying heterotopic neurons in WM, in patients with mTLE. The presence of such increases correlates with a poorer outcome.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15946336     DOI: 10.1111/j.1528-1167.2005.30904.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  9 in total

1.  What does flumazenil PET add to an evaluation for temporal lobectomy?

Authors:  William H Theodore
Journal:  Epilepsy Curr       Date:  2006 Jan-Feb       Impact factor: 7.500

2.  PET imaging in pediatric neuroradiology: current and future applications.

Authors:  Sunhee Kim; Noriko Salamon; Hollie A Jackson; Stefan Blüml; Ashok Panigrahy
Journal:  Pediatr Radiol       Date:  2009-11-24

3.  PET of serotonin 1A receptors and cerebral glucose metabolism for temporal lobectomy.

Authors:  William H Theodore; Ashley R Martinez; Omar I Khan; Clarissa J Liew; Sungyoung Auh; Irene M Dustin; John Heiss; Susumu Sato
Journal:  J Nucl Med       Date:  2012-07-10       Impact factor: 10.057

Review 4.  PET studies in epilepsy.

Authors:  Ismet Sarikaya
Journal:  Am J Nucl Med Mol Imaging       Date:  2015-10-12

5.  Converging PET and fMRI evidence for a common area involved in human focal epilepsies.

Authors:  H Laufs; M P Richardson; A Salek-Haddadi; C Vollmar; J S Duncan; K Gale; L Lemieux; W Löscher; M J Koepp
Journal:  Neurology       Date:  2011-08-17       Impact factor: 9.910

6.  Advanced [(18)F]FDG and [(11)C]flumazenil PET analysis for individual outcome prediction after temporal lobe epilepsy surgery for hippocampal sclerosis.

Authors:  J Yankam Njiwa; K R Gray; N Costes; F Mauguiere; P Ryvlin; A Hammers
Journal:  Neuroimage Clin       Date:  2014-11-27       Impact factor: 4.881

Review 7.  Epilepsy surgery: eligibility criteria and presurgical evaluation.

Authors:  Philippe Ryvlin; Sylvain Rheims
Journal:  Dialogues Clin Neurosci       Date:  2008       Impact factor: 5.986

8.  Role of neuroimaging in the presurgical evaluation of epilepsy.

Authors:  Tim Wehner; Hans Lüders
Journal:  J Clin Neurol       Date:  2008-03-20       Impact factor: 3.077

9.  Periventricular [(11)C]flumazenil binding for predicting postoperative outcome in individual patients with temporal lobe epilepsy and hippocampal sclerosis.

Authors:  Josiane Yankam Njiwa; Sandrine Bouvard; Hélène Catenoix; François Mauguiere; Philippe Ryvlin; Alexander Hammers
Journal:  Neuroimage Clin       Date:  2013-09-03       Impact factor: 4.881

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.